Workforce and Training COVID-19 Vaccination Programme

NHS England and NHS Improvement

Workforce and Training COVID-19 Vaccination Programme

Reviewing workforce requirements for vaccination centres – New Vaccines

22.04.2021 v5.1

OFFICIAL SENSITIVE – NOT FOR WIDER CIRCULATION

2 |

Section Description Page

Introduction • Summary of this document 3

Workforce design principles

• Principles used to design the national workforce model and outline

of the clinical limitations when looking to deliver local variations of

these models

4-7

Standardised key • Explains the symbols used in all the workforce model diagrams 8

Recommended models

• Vaccine characteristics matrix

• Outline of the national pod models for Pfizer, AstraZeneca and

Moderna based on vaccine characteristics

9-12

Model adaptations

• Alternative models for stable, non dilution vaccines to improve

throughput or reduce staffing requirements

• Alternative models to use in case of legislation constraints

13-15

Annex

• Workforce summary of roles for one vs. multi-pod site for

recommended models

• Role of the Clinical Supervisor• Workforce change control process

16-23

Contents

3 |

Introduction

This document provides guidance on the optimal workforce models for vaccination centres, based on the characteristics of the vaccine. It

follows the design principles of the standard “Pod” model (set out in the pod design specification document, previously distr ibuted).

• An optimal workforce pod model is proposed for each vaccine (section “Recommended Models”). These were designed following

extensive engagement and testing, and enable efficient throughput while taking into account patient safety and workforce limitations.

• Variations to the pod model may be required (ie due to vaccine characteristics, legislation or workforce constraints) or recommended

(ie when the staffing structure or throughput can be improved):

• Vaccine characteristics: The standard pod model was designed agnostic of vaccination type and based on the known

characteristics at the point of approval. It was designed to maximise throughput within acceptable safe staffing limitations.

Specific characteristics of each vaccine mean we can now consider further optimising the workforce roles to improve efficiency

(section “Model Adaptations”).

• Legislation considerations: The standard pod model was designed to deliver the vaccination programme under the National

Protocol. However, there are instances that require vaccination delivery under different nationally agreed guidance and

legislation (such as PGD and PSD) which require slight remodeling of the staffing structure (section “Model Adaptations”).

• All deviations from the standard pod model should adhere to the workforce design principles (section “Principles”). If deviations are

outside the models in this document, local teams should follow the formal approval process (see Annex 5).

4 |

Workforce design principles under the National Protocol

Adapting the workforce structure is permitted if the guidelines set out in this document are followed, and safe clinical and operational delivery of the vaccination is maintained.

This includes ensuring the following design principles are maintained:

• Any changes to the standard model must comply with the medicines regulations.

• Throughput must be continuously optimised and further modelling simulation and real-life experience analysis carried out to

ensure efficient vaccination delivery.

• Minimise role changes between pod models so that pods can administer different vaccines on different days.

• Split the vaccination stages under the National Protocol to optimise throughput.

• Optimise the use of the unregistered workforce to ensure scalability and sustainability of the workforce model.

• Appropriate clinical and operational supervision and escalation must be in place.

• Workforce must be appropriately trained to deliver all vaccines that may be delivered at a single location.

• Physical distancing of 2 metres remains standard practice in all health and care settings.

• As workforce changes are implemented, safety and quality metrics should be in place locally to track and assess the impact

of these changes to ensure that clinical safety of the service is maintained.

• Changes to the workforce model must be recorded through the Workforce Planning Tool on Foundry and approved by the

RDCs.

5 |

Workforce design red lines under the National Protocol

Clinical assessment and consent:

• The clinical assessment and consent process must be carried out by a trained registered healthcare professional only. Please note that not all registered healthcare professionals can

undertake this task. Please consult the “Characteristics of Staff” section in the National Protocol for Pfizer, AstraZeneca and Moderna for full information on accepted staffing groups.

• The use of self-assessment apps or non-registered workforce, to support with pre-screening prior to arriving at the vaccination centre, is permitted but the actual assessment and

consent on site must be carried out by a registered healthcare professional.

• There should be sufficient ratio of clinical assessors to pod staffing to meet throughput demands and avoid a bottleneck before the vaccination stage.

Vaccine preparation:

• Pfizer vaccine: Dilution and drawing up should be carried out by experienced staff, under the supervision of a doctor, nurse or pharmacist (if not one themselves). This includes

experienced trained and competent unregistered staff with experience of aseptic non-touch technique, for example, those working as part of NHS aseptic teams or experienced HCAs

working under supervision.

• Moderna vaccine: This vaccine does not require dilution. However drawing up of this vaccine should be carried out by experienced staff only. They can be unregistered staff working

as part of Aseptic teams or experienced HCAs. Volunteer vaccinators or unregistered staff without adequate experience are not currently permitted to draw up.

• The Moderna and Pfizer messenger RNA vaccine molecules are inherently unstable and particularly vulnerable to damage if mishandled. Any damage can lead to inefficacy of the

vaccine. Hence the recommendation that those drawing up these vaccines have adequate prior experience.

• AstraZeneca vaccine: This vaccine does not require dilution. However, it is presented in a multidose vial so it requires drawing up using aseptic technique. The drawing-up and

vaccine administration can be completed by the same individual if this is considered locally to be more efficient. Registered and unregistered vaccinators can only be responsible for

both the draw-up and the administration of the vaccine if:

a) They have experience of and received specific training on drawing up of multi-dose vials as well as aseptic technique and infection control procedures. This will need to be provided locally as there is no national provision. This needs to be structured training and not just a ‘see one, do one approach’.

b) They have been signed off as competent to draw up the vaccine by a registered healthcare professional with experience and knowledge of aseptic technique.

c) They work under the direct supervision of the Band 6 Clinical Supervisor role. Unregistered vaccinators will need to be directly supervised by a doctor, nurse or pharmacist. Supervision ratio is based on individual’s experience and competency. For inexperienced staff, a 1:2 ratio is recommended until the supervisor is assured of competency.

If these three conditions cannot be met, a minimum banded 5 RHCP will be responsible for the draw-up of the vaccine. They can then either administer the vaccination themselves

or pass it to the registered or unregistered vaccinator, ensuring the local SOP for safe transfer is followed. Use of unregistered staff without appropriate experience of drawing up

may affect throughput and numbers of doses that can be drawn up from vials.

https://www.gov.uk/government/publications/national-protocol-for-covid-19-mrna-vaccine-bnt162b2-pfizerbiontech

https://www.gov.uk/government/publications/national-protocol-for-covid-19-vaccine-astrazeneca-chadox1-s-recombinant

https://www.gov.uk/government/publications/national-protocol-for-covid-19-vaccine-moderna

6 |


Vaccine administration:

• The minimum standard for the vaccinator is a registered or an unregistered Vaccinator or a Band 3 HCA, which can be banded higher as determined locally. The vaccinator can only

administer the vaccine under the supervision of a registered healthcare professional.

Post-vaccination observation:

• Pfizer and Moderna vaccines: A post vaccination observation period of 15 minutes is required.

• AstraZeneca: It is only required if the person being vaccinated is driving. However, the estate, access to equipment and access to staff trained in BLS should remain in place should

this requirement change or be needed in the future.

Leadership and supervision:

• Appropriate and sufficient escalation points (clinical and non-clinical) must be in place to ensure patient safety at all stages of the process and that site(s) run smoothly. The national

design incorporates these appropriate levels of supervision throughout, ie a clinical lead who has overall accountability for the full process is available on site each day. This is usually

the band 8a/8b role depending on local models.

• Under the National Protocol, a senior lead role, referred to as “Clinical Supervisor”, is required and should be accountable for the clinical supervision and accountability of the whole

vaccination process. They must be a registered doctor, nurse or pharmacist trained and competent in all aspects of the protocol. The pod workforce model has assigned this function

to the Band 8a Nursing Manager role which is an above pod level function and complies with the legislation. Annex 3 describes the difference between the “Clinical Supervisor” in the

National Protocol and the role of “COVID-19 Vaccination Programme – RHCP Clinical Supervisor (Vaccinations)” Band 6, which undertakes clinical supervisory responsibilities

specific to practice within a single POD.

• All supervision requirements are clearly defined in the National Protocol for Pfizer, AstraZeneca and Moderna and should be followed as minimum standard to be in line with the

legislation.

Non-clinical staff:

• Local assessment for the right number of non-clinical staff needed (ie stewards, Front of House).

https://www.gov.uk/government/publications/national-protocol-for-covid-19-mrna-vaccine-bnt162b2-pfizerbiontech

https://www.gov.uk/government/publications/national-protocol-for-covid-19-vaccine-astrazeneca-chadox1-s-recombinant

https://www.gov.uk/government/publications/national-protocol-for-covid-19-vaccine-moderna

7 |


Training:

• Staff should be assessed for competency against the PHE COVID-19: vaccinator competency assessment tool by a supervisor. Registered Health Care professionals can complete a

self-assessment.

• Face to face training is required for all non-registered vaccinators. Refresher face to face training for registered healthcare professionals should be considered to ensure consistency

of practice regarding Intra Muscular (IM) injection technique; dilution; and drawing up of vaccines – practitioners must be confident in these tasks.

Other considerations:

• Modelling simulation data shows that the most efficient way of operating is by splitting roles into clinical assessment, vaccine preparation and administration and post-vaccination

observation, under the National Protocol. However, there is flexibility for when splitting the roles is not possible (sites operating under a PGD model) or unviable (ie from a workforce

perspective).

https://www.gov.uk/government/publications/covid-19-vaccinator-competency-assessment-tool

8 |

Standardised key for the pod design models

User

Front of House

Steward (volunteer)Resus Equipment

PPE don area

Vaccine Preparation Bench

PPE doff area

Assessment Station

St John Ambulance (Post Vaccination Observation & Patient Advocate)

Trolley

Registered HCP B5

Private office for clinical assessment

Vaccine Station

Registered HCP B6

Admin Support

Health Care Assistant

Check-in station8a Nursing Manager

Medical Director

Operations Director

Senior Manager

Pharmacy Team

Vaccinator

0 Arrival & check-in

1 Clinical assessment

2 Delivery

3 Post observation

Prescriber

Clinical roles: Support roles: Leadership roles: Logistics & estates: Vaccination stages:

STANDARDISED KEY

The National Protocol enables elements of the vaccination process to be split and delegated to different staff members. Through simulation and modelling the splitting

of the tasks in the pathway proved to be the most efficient operating model for the approved COVID-19 vaccinations.

9 |

VaccineDoes this vaccine

require dilution?

Can an inexperienced

non-registered

vaccinator draw up?*

Does this vaccine

require 15 min

post- observation?

Does the model

require full team of

SJA observers?

Pfizer

Astra Zeneca

Moderna

You should consider the vaccine characteristics when adopting a pod model

This matrix will continue to be updated as new vaccines become available.

Recommended

workforce model

Post vaccination observation

team requirement

Model 1 Full observation team

Model 2 Reduced observation team

Model 3 Full observation team

The following vaccine characteristics determine variations in workforce requirements and which workforce model should be adopted:

• Characteristics around vaccine preparation determine the operational model required (Model 1-3, see slides 9-11):

• Model 1: Pfizer requires dilution – dilution must be done by a registered healthcare professional, drawing up must be done by experienced staff

• Model 2: AstraZeneca does not require dilution – drawing up can be done by registered or non-registered staff, with or without previous experience, with appropriate

training and supervision

• Model 3: Moderna does not require dilution, but has more complex characteristics – drawing up must be done by experienced staff (registered or unregistered)

• Vaccine specific characteristics must be considered to determine the staff required in the observation area post-vaccination:

• Full post-vaccination observation team (usually two SJA volunteers) for vaccines which require 15 minutes observation

• Reduced team (one SJA volunteer) to offer basic life support if necessary

• Further variation opportunities can be adopted for AstraZeneca (Model 2) to increase throughput or to reduce the pressure on staff. Slides 11-12 refer to these variations.

10 |

Recommended workforce pod model 1 under National Protocol:Pfizer vaccine

VOLUME

PER POD

PER DAY:

520

Key Role No.

Vaccinator 2/pod

Registered Health Care Professional (B5) 6/pod

RHCP – Clinical Supervisor (B6) 1 +1/3x pod

Health Care Assistant 1/pod

Vaccine Admin Support 2/pod

Administrator (Front of House) 2/pod

Steward 5/pod

SJA Volunteer 3/pod

Nursing Manager 1/max 3 pods

Senior Manager 1/one pod site

Medical Director 1/site

Operations Director 1/site

Pharmacy Team Required

Specifications:

• Vaccine preparation is separated from the vaccine administration and must

be by a registered healthcare professional

• The vaccinator role can be filled by registered or unregistered staff,

appropriately trained and supervised

• Post-vaccination observation is required, a full team of SJA volunteers is

needed (1x patient advocate pre-vaccination and 2x post-vaccination

observation)

• Pharmaceutical team – responsible for process oversight on drawing up

(local flexibility).

0 Arrival & check-in 1 Clinical assessment 2 Delivery 3 Post observation

Car

Park 1Exit

2 3

Entrance

**

0

*Staff only required for single pod site.

**Staff only required for multiple pod site.

Leadership team

* **

11 |

Key Role No.

Vaccinator 3/pod






Steward 5/pod

SJA Volunteer 2-3/pod







Car

Park 1Exit

2 3

Entrance

**

0



Leadership team

* **

VOLUME

PER POD

PER DAY:

520

Specifications:

• The draw-up activity can be separated from the vaccine administration or

delivered together

• The draw-up and vaccinator role(s) can be filled by registered or unregistered

staff, appropriately trained and supervised

• Post-vaccination observation is not required, but reduced SJA staffing is still

needed to provide BLS services, respond to any anaphylaxis incidents and

supporting patients with questions and concerns


(local flexibility)

Recommended workforce pod model 2 under National Protocol:AstraZeneca vaccine

12 |

Recommended workforce pod model 3 under National Protocol:Moderna Vaccine

VOLUME

PER POD

PER DAY:

520

Key Role No.

Vaccinator 2/pod






Steward 5/pod

SJA Volunteer 3/pod






Specifications:

• The draw-up activity is separated from the vaccine administration and must

be done by an experienced and competent individual

• The vaccinator role can be filled by registered or unregistered staff,

appropriately trained and supervised

• Post-vaccination observation is required, a full team of SJA volunteers is

needed (1x patient advocate pre-vaccination and 2x post-vaccination

observation)


(local flexibility).


Car

Park 1Exit

2 3

Entrance

**

0



Leadership team

* **

***The following staff groups can be considered for the role

responsible for drawing up Moderna vaccine:

• Registered healthcare professionals

• Unregistered staff as part of Aseptic teams

• Experienced healthcare assistants

***

13 |

What this model shows:What this model lets

you do:Considerations:

• Utilise the Standard Pod roles to

open a third vaccination lane

• Draw-up and vaccine administration

is done together by the same

individual

• One extra B5 RHCP is added to

increase the flow of clinical

assessment activity

• Post vaccination not required

• Maximise

throughput

• Minimise team

changes between

vaccines

• Reduce post

observation

vaccination team &

skillmix

• Estate impact of

opening a third lane

• Increased

requirement for Band

5 RHCP

• Local requirement for

training the

Vaccinator to draw

up

What this model shows:What this model lets

you do:Considerations:

• Remove 1 x B5 RHCP from the

Standardised Pod Model

• Vaccinator can be trained to both

draw-up and administer non-

dilution vaccines


• Reduce the

requirement to

recruit / roster B5

RHCP

• Reduce post

observation

vaccination team &

skillmix

• Reduced throughput

• Local requirement for

training the Vaccinator to

draw up

• Different rostering

structure between

vaccines

Stable vaccines that do not require dilution provide an opportunity with its simpler logistics and preparation to redeploy certain roles within the base pod model to improve throughput or

reduce staffing requirements. Each vaccination centre should carry out adaptations, when appropriate. Below are the approved variations.

Please consider post-vaccination observation requirements depending on the vaccine type.

Workforce adaptations for model 2 (1)

DAILY VOLUME:

624i) Variation to increase throughput

DAILY VOLUME:

454ii) Variation to reduce pressure on

Registered Healthcare Practitioners

*Staff only required for single pod site. ** Staff only required for multiple pod site.

***There is scope to increase the number of vaccination stations to 3 within one pod. Consider repurposing some of the

waiting area space to increase the space allocated for the overall vaccination area.

*Staff only required for single pod site. ** Staff only required for multiple pod site. ***There is scope to decrease the number of clinical assessors required to 4, further reducing the workforce pressure. However, further analysis (using simulation software and/or real life experience) might be required to support this.

14 |

What this model shows:What this model

lets you do:Considerations:

• Remove 2 x Vaccinators from the

standard pod model if sufficient

staffing is not available

• Have 2x Band 5s inside the pod to

both draw-up and administer the

vaccine


• Reduce total

staffing demand

• Reduce post

observation

vaccination team

& skillmix

• Reduced throughput

• Different rostering

structure between

vaccines

DAILY VOLUME:

454iii) Variation to reduce pressure on

Non-Registered Practitioners

*Staff only required for single pod site. ** Staff only required for multiple pod site. ***There is scope to decrease the number of clinical assessors required to 4, further reducing the workforce pressure. However, further analysis (using simulation software and/or real life experience) might be required to support this.

Workforce adaptations for model 2 (2)

15 |

What this model shows***:What this model lets you

do:Considerations:

• Vaccination stages are delivered

by the same registered

practitioner and are not split

• The vaccination cells number is

illustrative (note gridded cell)

and is subject to local space and

availability

• Workforce model to

allow the delivery of

vaccines under a PGD

or when it is not viable

to split the vaccination

roles

• Further consideration

needed from an

estate/logistics

perspective to

determine the viable

number of

vaccination cells

What this model shows:What this model

lets you do:Considerations:

• Alternative operating model

introducing the Prescriber role

• Designed to be a short term

solution for new vaccines

• Prescriber oversees the end to

end vaccination process

• Model allows

the delivery of

vaccines under

a PSD****

• This model significantly reduces

throughput and puts pressure on

available Prescribers

*Staff only required for single pod site. ** Staff only required for multiple pod site.

***Further analysis (using simulation software and/or real life experience) might be required to support this model and determine its optimal efficiency concerning workforce and operational aspects.

****A prescriber is required to sign the PSD under the Vaccination Centre model and will require the prescriber to oversee the end to end vaccination process per individual.

The standard pod model has been designed to deliver the vaccination programme under the National Protocol. The following models can be considered, but please note these will

impact the workforce requirements and throughput levels:

Workforce adaptations for PGD and PSD for all models

DAILY VOLUME:

TBC**i) Vaccine delivery under a PGD

DAILY VOLUME:

312ii) Vaccine delivery under a PSD


• The tables in this Annex outline the workforce requirements at each vaccination stage to support the safe and effective delivery of vaccinations across a single vs. a multiple pod site for

Pfizer (Model 1).

• It shows the crude numbers needed at any given time for the models to operate. It does not account for FTE sick leave, breaks, 2 shifts per day.

• The site size dictates the required governance structure, which can vary between a one pod site vs multiple pod site as scaling involves increased management, governance and

accountability. This is a recommended workforce structure and is subject to local flexibility and adjustment.

Annex 1.1Workforce summary for Model 1 under National Protocol


Stage Role DescriptionTotal no of workforce required

Narrative and commentsOne pod site Multiple pod site

Site registration Front of House (Band 2)• Responsible for patient check-in and pod allocation.

• Responsible for patient queries on the day.2 2 per pod

For scaling purposes, the numbers show the

roles needed relative to the pod ratio, but do

not imply the location of the roles inside the

pod.

Clinical assessment

and consent

Registered healthcare

professional as per National

Protocol (Band 5)

• Responsible for the patient clinical assessment pre-

vaccination.5 5 per pod

Vaccine preparation

Experienced registered

healthcare professional (Band

5) or vaccinator

• Responsible for diluting and drawing up the vaccine

(experienced, trained and competent staff)1 1 per pod

Vaccine

administration

Vaccinator (registered or

unregistered)

• Responsible for the delivery of vaccination.

• Responsible for the disposal of clinical waste and

change of PPE (when required).

2 2 per pod

Vaccine data

recordingAdmin Support (Band 3)

• Responsible for patient record keeping.

• Responsible for recording vaccination data (such as

batches, numbers).

2 2 per pod

Waste managementHeath Care Assistant (HCA)

(Band 3)

• Responsible for sanitisation and infection control (eg

wipe down surfaces).

• Support the vaccination process.

1 1 per pod

Site Stewarding Marshal • Responsible for patient flow management. 5 5 per pod

Patient guidance SJA Patient Advocate• Responsible for answering patient queries and

addressing any concerns.1 1 per pod

Post vaccination

observationSJA Volunteer

• Responsible for managing the post vaccination

observation area and providing BLS.2 2 per pod





Clinical

Supervision &

Escalation


professional (Band 6)

• Supervision of the vaccination activity and staff within

the pod and observation area.1 1 per pod –


professional (Band 6)• Escalation point for clinical assessment. 0 1 per max 3 pods

Within the one pod site, the clinical assessors can

escalate to the senior manager. Scaling up, we

anticipate the need for a Band 6 as direct

escalation point, one responsible for up to three

pods.

Nursing Manager

(Band 8a)

• Responsible for clinical escalations.

• Responsible for overseeing the clinical activity for the

pod and clinical assessment area.

0 1 per max 3 pods

Within the one pod site, a senior manager is able

to oversee both clinical and operational activity.

Scaling up to multiple pods, this role requires

separation of responsibility; therefore, we propose

that instead of a senior manager, a

nursing manager is responsible for the clinical

oversight of a maximum of 3 pods and there is on-

site presence of an ops director (see below)

responsible for operational oversight.

Senior Manager (Band

8c-d)

• Responsible for clinical and operational oversight,

governance of the site and staff supervision.1 0

Overall site

management

Medical Director

• Responsible for clinical leadership and governance of

the site(s).

• Responsible for clinical escalations above the nursing

manager or senior manager.

1 per site to cover

remote oversight

of difficult clinical

queries

At least 1 per Lead

Trust covering

multiple sites (remote)

We anticipate that a medical director can oversee

multiple sites remotely. This role may be covered

by the GP in the PCN model.

Operations Director

• Responsible for non-clinical leadership and operational

delivery of mass vaccination site(s).

• Responsible for ensuring all workforce, consumables

and equipment are in place.

At least 1 per lead

trust covering

multiple sites

(remote)

1 per site (on site)

We anticipate that the Ops Director can oversee

multiple one pod sites remotely. For multiple pod

sites, this role may be required in-person, dedicated

to that site.

Pharmacy Team

Pharmacy input and oversight must be considered in the mass vaccination sites to maintain product integrity of the Vaccine, ensuring that appropriate cold chain processes are in place

and that the staff carrying out tasks are adequately training to handle the vaccine(s). There will be a mix of new HC Professionals and new recruits hence good pharmaceutical oversight

is essential to ensure patient safety. Specifically, management of all aspects of ordering, receipt, storage and onward supply from stock of vaccine and medicines should be provided by

a senior member of the local Pharmacy Team.

SOPs have been developed to support this process and are available on Specialist Pharmacy Services websites.




AstraZeneca (Model 2).













pod.

Clinical assessment

and consent



Protocol (Band 5)


vaccination. 5 5 per pod

Vaccine preparation


professional (Band 5) or

vaccinator

• Responsible for drawing up the vaccine (RHCP or

competent non registered staff)1 1 per pod

Vaccine

administration


unregistered)




2 2 per pod

Vaccine data




batches, numbers).

2 2 per pod


(Band 3)




1 1 per pod




Post vaccination



observation area and providing BLS.1 1 per pod*





Clinical

Supervision &

Escalation











pods.

Nursing Manager

(Band 8a)




0 1 per max 3 pods











8c-d)



Overall site

management

Medical Director


the site(s).



1 per site to cover

remote oversight


queries

At least 1 per Lead

Trust covering





Operations Director





At least 1 per lead

trust covering

multiple sites

(remote)





to that site.

Pharmacy Team









Moderna (Model 3).













pod.

Clinical assessment

and consent



Protocol (Band 5)


vaccination. 5 5 per pod

Vaccine preparation

Experienced registered

healthcare professional (Band

5) or vaccinator

• Responsible for drawing up the vaccine (experienced,

trained and competent staff)1 1 per pod

Vaccine

administration


unregistered)




2 2 per pod

Vaccine data




batches, numbers).

2 2 per pod


(Band 3)




1 1 per pod




Post vaccination



observation area and providing BLS.2 2 per pod





Clinical

Supervision &

Escalation











pods.

Nursing Manager

(Band 8a)




0 1 per max 3 pods











8c-d)



Overall site

management

Medical Director


the site(s).



1 per site to cover

remote oversight


queries

At least 1 per Lead

Trust covering





Operations Director





At least 1 per lead

trust covering

multiple sites

(remote)





to that site.

Pharmacy Team







The term ‘clinical supervisor’ in the National Protocols applies to a senior lead role accountable for the clinical supervision of the whole

vaccination process. This role is different to the health care professional responsible for supervising non-registered staff within a single pod (the

Band 6 ‘COVID-19 Vaccination Programme - RHCP Clinical Supervisor (Vaccinations)’ role).

The remit of the clinical supervisor is defined as: ‘A clinical supervisor, who must be a registered doctor, nurse or pharmacist trained and

competent in all aspects of the protocol, must be present and take overall responsibility for provision of vaccination under the protocol at all times

and be identifiable to service users.’’

The pod workforce model assigns this function to the Band 8a Nursing Manager role, an above pod level function which complies with the

legislation. This role could equally be carried out by a doctor or pharmacist. The Band 8a Nursing Manager job description includes the following

responsibilities:

‘’The post holder will be responsible for clinical oversight of multiple vaccination and post-vaccination observation pods within a vaccination

centre.’’

And

‘’Ensure the centre and national policies including Patient Group Directions (PGDs) and national protocols or standard operating procedures

(SOPs) are followed.’’

The Band 6 ‘COVID-19 Vaccination Programme - RHCP Clinical Supervisor (Vaccinations)’ role also undertakes a clinical supervisory

role by overseeing a team of vaccinators, however responsibilities are specific to practice within a single pod – their role is to: ‘’Undertake a

clinical supervisory role, overseeing several non-registered vaccinators, Band 5 HCP for clinical assessment and drawing-up and post vaccination

observation SJA volunteers.’’

Further details on the legal mechanisms and national protocols: https://www.england.nhs.uk/coronavirus/covid-19-vaccination-programme/legal-

mechanisms/

Annex 4The role of the Clinical Supervisor

https://www.england.nhs.uk/coronavirus/covid-19-vaccination-programme/legal-mechanisms/

23 |

Each variation to the workforce model needs to go through a change control process which is embedded within the Workforce Planning Tool on Foundry. A minimum of

14 days should be allowed for the relevant approvals to be sought and supply chains notified.

The authorising email on

the request needs to be

the RDC

Access the request to change via the Workforce

Planning Tool 1. Add the details around the proposed

changes 2.

An email to request the change will go to

the RDC for approval.

In addition to this it will go to the following

workstreams within the national programme:

• Workforce

• Clinical

• Strategy

• EECL

It will also go through the delivery model

governance process.

Once approved the modelling will be updated in

Foundry to reflect the change.

The components of the workforce planning tool that are able to be modified are:

• Site – designed to be localised to specific location

• Throughput of the pod model

• Workforce required to support delivery

• Date range for the change

Approval process 3.

Any proposed changes should adhere to

nationally agreed guidance and legislation

and should be in line with the workforce

design principles and red lines. !

Annex 5Workforce Change Control Process


Documents

Workforce and Training COVID-19 Vaccination Programme